Show simple item record

dc.contributor.authorEchezarreta López, María Magdalena 
dc.contributor.authorSantoveña Estévez, Ana María
dc.contributor.authorSuárez González, Javier
dc.contributor.authorCáceres Pérez, Amor R.
dc.contributor.authorRuiz Noda, Zuleima
dc.contributor.authorMachado Rodríguez, Sara
dc.contributor.authorSoriano, Mabel
dc.contributor.authorFariña, José B.
dc.contributor.otherIngeniería Química y Tecnología Farmacéutica
dc.contributor.otherGrupo de investigación: Desarrollo galénico de medicamentos Instituto de investigación: Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias
dc.date.accessioned2024-04-29T20:05:30Z
dc.date.available2024-04-29T20:05:30Z
dc.date.issued2020
dc.identifier.urihttp://riull.ull.es/xmlui/handle/915/37312
dc.descriptionFinanciado por ProID2017010094. Desarrollo de nuevos medicamentos para el tratamiento de la tuberculosis pediátrica: formas farmacéuticas de administración oral. Convocatoria: 2017/1 PI.ACIISI.17.02.06. ISACAM. Instauración de un sistema para el aseguramiento de la calidad de medicamentos utilizados en el tratamiento del SIDA y enfermedades tropicales desatendidas Convocatoria: 2019/0028 INTERREG.18
dc.description.abstract(1)Background: First-lineantituberculosistreatmentinpaediatricsentailstheadministration of Isoniazid, Pyrazinamide, and Rifampicin. This study examines the possibility of developing a combined dose liquid formulation for oral use that would facilitate dose adjustment and adherence to treatment for younger children. (2) Methods: The active pharmaceutical ingredients stability under in vitro paediatric digestive pH conditions have been checked. The samples were studied as individual or fixed combined paediatric dosages to determine the pH of maximum stability. The use of hydroxypropyl-β-cyclodextrin to improve Rifampicin solubility and the use of ascorbic acid to increase the stability of the formulation have been studied. (3) Results: Maximum stability of combined doses was determined at pH 7.4, and maximum complexation at pH 8.0. Taking this into account, formulations presented the minimum dose of two active pharmaceutical ingredients dissolved. The addition of ascorbic acid at 0.1% w/v enables the detection of a higher remaining quantity of both drugs after three days of storage at 5 ◦C. (4) Conclusions: a formulation which combines the minimum paediatric dosages dissolved recommended by WHO for Isoniazid and Rifampicin has been developed. Future assays are needed to prolong the stability of the formulation with the aim of incorporating Pyrazinamide to the solution.en
dc.format.mimetypeapplication/pdf
dc.language.isoen
dc.relation.ispartofseriesPharmaceutics, 2020, 12, 195
dc.rightsLicencia Creative Commons (Reconocimiento-No comercial-Sin obras derivadas 4.0 Internacional)
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es_ES
dc.titleStability study of isoniazid and rifampicin oral solutions using hydroxypropyl-B-cyclodextrin to treat tuberculosis in paediatricsen
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/pharmaceutics12020195
dc.subject.keywordfirst-line antituberculosis paediatric treatmenten
dc.subject.keyworddose combinationen
dc.subject.keywordisoniaziden
dc.subject.keywordpyrazinamideen
dc.subject.keywordrifampicinen


Files in this item

This item appears in the following Collection(s)

Show simple item record

Licencia Creative Commons (Reconocimiento-No comercial-Sin obras derivadas 4.0 Internacional)
Except where otherwise noted, this item's license is described as Licencia Creative Commons (Reconocimiento-No comercial-Sin obras derivadas 4.0 Internacional)